CAS No.: 1041434-82-5
Product introduction:Peramivir is a potent and selective inhibitor of influenza virus neuraminidase, an enzyme essential for viral replication and release from infected cells. It belongs to the class of cyclopentane-based neuraminidase inhibitors, structurally distinct from other agents such as oseltamivir and zanamivir. Peramivir is administered intravenously, making it particularly valuable for treating hospitalized patients or those unable to take oral medications. It received emergency use authorization during the 2009 H1N1 pandemic and was later approved in multiple countries, including Japan, the United States, China, and South Korea. The compound is marketed under the brand name Rapivab® in the United States.
CAS No.:1041434-82-5
Peramivir is a white to off-white crystalline powder with the molecular formula C₁₅H₂₈N₄O₄ and a molecular weight of approximately 328.41 g/mol. Its chemical name is (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid. The compound is freely soluble in water and exhibits high binding affinity to influenza neuraminidase, with a slow dissociation rate that allows for a single intravenous dose. It is stable under normal storage conditions when kept dry and protected from light.
Core Functions:
Active pharmaceutical ingredient (API) in Rapivab® for the treatment of acute uncomplicated influenza A and B in adults and pediatric patients
Intravenous antiviral therapy for hospitalized patients with severe influenza or those requiring rapid viral suppression
Investigational use in combination therapies for seasonal and pandemic influenza strains
Research use in virology studies of neuraminidase inhibition and drug resistance mechanisms
Reference standard for analytical method development and quality control in pharmaceutical testing
Contact: Tony
Phone: 008618700976396
E-mail: sales@fulecare.com
Whatsapp:008618700976396
Add: Zhang Ba 6 Road,Hi tech zone,Xi'an Shaanxi Province,China
